Spots Global Cancer Trial Database for tkis
Every month we try and update this database with for tkis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination of Metformin With Gefitinib to Treat NSCLC | NCT01864681 | NSCLC EGFR Gene Ampli... Advanced Cancer Stage IIIB NSCL... Stage IV NSCLC | Gefitinib and M... Gefitinib and p... | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia | NCT03331211 | Leukemia, Lymph... | TKIs | 14 Years - | Nanfang Hospital, Southern Medical University | |
| Combination of Metformin With Gefitinib to Treat NSCLC | NCT01864681 | NSCLC EGFR Gene Ampli... Advanced Cancer Stage IIIB NSCL... Stage IV NSCLC | Gefitinib and M... Gefitinib and p... | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study | NCT05231863 | Breast Cancer | TKIs | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance | NCT06202599 | Bone Sarcoma Soft Tissue Sar... Refractory Tumo... | Fruquintinib | - | Peking University People's Hospital | |
| An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | NCT01932229 | NSCLC | Afatinib treatm... | - | Sheba Medical Center | |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | NCT04971226 | Chronic Myeloid... | Imatinib Nilotinib Bosutinib Dasatinib Asciminib | 18 Years - | Novartis | |
| TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | NCT01883219 | Philadelphia Ch... Stem Cell Trans... Minimal Residua... | TKIs | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT | NCT05535998 | Hepatocellular ... | TACE-HAIC TACE Targeted therap... PD-1 inhibitors | 18 Years - | Sun Yat-sen University | |
| An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | NCT01932229 | NSCLC | Afatinib treatm... | - | Sheba Medical Center | |
| A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | NCT02081378 | Chronic Myeloge... Philadelphia Ch... | Asciminib (ABL0... Nilotinib Imatinib Dasatinib | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
